Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive factors for survival outcomes of oligometastatic prostate cancer patients treated with metastases-directed therapy: a recursive partitioning-based analysis.
Franzese C, Di Brina L, D'Agostino G, Franceschini D, Comito T, De Rose F, Tozzi A, Navarria P, Scorsetti M. Franzese C, et al. Among authors: d agostino g, franceschini d. J Cancer Res Clin Oncol. 2019 Oct;145(10):2469-2479. doi: 10.1007/s00432-019-03007-w. Epub 2019 Aug 23. J Cancer Res Clin Oncol. 2019. PMID: 31444549
Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node-negative breast cancer.
Livi L, Meattini I, Saieva C, Franzese C, Di Cataldo V, Greto D, Franceschini D, Scotti V, Bonomo P, Nori J, Sanchez L, Vezzosi V, Bianchi S, Cataliotti L, Biti G. Livi L, et al. Among authors: franceschini d. Cancer. 2012 Jul 1;118(13):3236-43. doi: 10.1002/cncr.26647. Epub 2011 Oct 25. Cancer. 2012. PMID: 22028054 Free article.
Predictive factors of [18F]-Choline PET/CT in 170 patients with increasing PSA after primary radical treatment.
Detti B, Scoccianti S, Franceschini D, Cipressi S, Cassani S, Villari D, Gacci M, Pupi A, Vaggelli L, Saieva C, Pertici M, Livi L, Ceroti M, Nicita G, Carini M, Biti G. Detti B, et al. Among authors: franceschini d. J Cancer Res Clin Oncol. 2013 Mar;139(3):521-8. doi: 10.1007/s00432-012-1354-4. Epub 2012 Nov 27. J Cancer Res Clin Oncol. 2013. PMID: 23183655
Radiotherapy boost dose-escalation for invasive breast cancer after breast-conserving surgery: 2093 patients treated with a prospective margin-directed policy.
Livi L, Meattini I, Franceschini D, Saieva C, Meacci F, Marrazzo L, Gerlain E, Desideri I, Scotti V, Nori J, Sanchez LJ, Orzalesi L, Bonomo P, Greto D, Bianchi S, Biti G. Livi L, et al. Among authors: franceschini d. Radiother Oncol. 2013 Aug;108(2):273-8. doi: 10.1016/j.radonc.2013.02.009. Epub 2013 Mar 13. Radiother Oncol. 2013. PMID: 23490271
Prognostic role of human epidermal growth factor receptor 2 status in premenopausal early breast cancer treated with adjuvant tamoxifen.
Meattini I, Livi L, Saieva C, Franceschini D, Scotti V, Mangoni M, Loi M, Di Brina L, Zei G, Bonomo P, Greto D, Gelain E, Nori J, Sanchez LJ, Orzalesi L, Bianchi S, Biti G. Meattini I, et al. Among authors: franceschini d. Clin Breast Cancer. 2013 Aug;13(4):247-53. doi: 10.1016/j.clbc.2013.02.005. Epub 2013 May 15. Clin Breast Cancer. 2013. PMID: 23684167
Docetaxel in castration-resistant prostate cancer: a single-centre experience.
Detti B, Franceschini D, Saieva C, Di Brina L, Baki M, Meattini I, Di Cataldo V, Pasquetti EM, Furfaro I, Mancuso A, Simontacchi G, Livi L. Detti B, et al. Among authors: franceschini d. Cancer Invest. 2014 Nov;32(9):445-50. doi: 10.3109/07357907.2014.958233. Epub 2014 Sep 26. Cancer Invest. 2014. PMID: 25259606
Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer.
Detti B, Bonomo P, Masi L, Doro R, Cipressi S, Iermano C, Bonucci I, Franceschini D, Di Brina L, Bakhi M, Simontacchi G, Meattini I, Livi L. Detti B, et al. Among authors: franceschini d. World J Urol. 2015 Aug;33(8):1197-203. doi: 10.1007/s00345-014-1427-x. Epub 2014 Oct 24. World J Urol. 2015. PMID: 25342516
Cyberknife treatment for low and intermediate risk prostate cancer.
Detti B, Bonomo P, Masi L, Doro R, Cipressi S, Iermano C, Bonucci I, Franceschini D, Di Cataldo V, Di Brina L, Baki M, Simontacchi G, Meattini I, Carini M, Serni S, Nicita G, Livi L. Detti B, et al. Among authors: franceschini d. Cancer Invest. 2015 May;33(5):188-92. doi: 10.3109/07357907.2015.1019679. Epub 2015 Apr 1. Cancer Invest. 2015. PMID: 25831274
CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed.
Detti B, Bonomo P, Masi L, Doro R, Cipressi S, Iermano C, Bonucci I, Franceschini D, Di Brina L, Baki M, Simontacchi G, Meattini I, Carini M, Serni S, Nicita G, Livi L. Detti B, et al. Among authors: franceschini d. World J Urol. 2016 Mar;34(3):311-7. doi: 10.1007/s00345-015-1613-5. Epub 2015 Jun 11. World J Urol. 2016. PMID: 26062525
237 results